Zoetis Inc. Long-Term Debt
Zoetis Inc. (ZTS) had Long-Term Debt of $9.05 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt and Lease Obligation
us-gaap:LongTermDebtNoncurrent · last filed 2026-08-06
- 2026-06-30: Long-term Debt, Excluding Current Maturities $9.05B.
- 2026-03-31: Long-term Debt, Excluding Current Maturities $9.04B.
- 2025-12-31: Long-term Debt, Excluding Current Maturities $9.04B.
- 2025-09-30: Long-term Debt, Excluding Current Maturities $7.07B.
| Period end | Long-term Debt, Excluding Current Maturities | Long-term Debt, Excluding Current Maturities as first filed |
|---|---|---|
| 2026-06-30 | $9.05B 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $9.04B 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $9.04B 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $7.07B 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $5.23B 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $5.23B 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $5.22B 10-K · filed 2026-02-12 | |
| 2024-09-30 | $6.57B 10-Q · filed 2024-11-04 | |
| 2024-06-30 | $6.56B 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $6.56B 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $6.56B 10-K · filed 2025-02-13 | |
| 2023-09-30 | $6.55B 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $6.55B 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $6.56B 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $6.55B 10-K · filed 2024-02-13 | |
| 2022-09-30 | $5.21B 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $5.22B 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $5.23B 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $6.59B 10-K · filed 2023-02-14 | |
| 2021-09-30 | $6.59B 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $6.59B 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $6.59B 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $6.59B 10-K · filed 2022-02-15 | |
| 2020-09-30 | $6.59B 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $7.19B 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $5.96B 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $5.95B 10-K · filed 2021-02-16 | |
| 2019-09-30 | $6.45B 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $6.45B 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $6.44B 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $6.44B 10-K · filed 2020-02-13 | |
| 2018-09-30 | $6.44B 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $4.96B 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $4.95B 10-Q · filed 2018-05-02 | |
| 2017-12-31 | $4.95B 10-K · filed 2019-02-14 | |
| 2017-10-01 | $4.95B 10-Q · filed 2017-11-02 | |
| 2017-07-02 | $3.72B 10-Q · filed 2017-08-08 | |
| 2017-04-02 | $3.72B 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $4.47B 10-K · filed 2018-02-15 | |
| 2016-10-02 | $4.47B 10-Q · filed 2016-11-03 | |
| 2016-07-03 | $4.46B 10-Q · filed 2016-08-05 | |
| 2016-04-03 | $4.46B 10-Q · filed 2016-05-06 | |
| 2015-12-31 | $4.46B 10-K · filed 2017-02-16 | |
| 2015-09-27 | $3.23B 10-Q · filed 2015-11-05 | |
| 2015-06-28 | $3.24B 10-Q · filed 2015-08-06 | |
| 2015-03-29 | $3.24B 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $3.62B 10-K · filed 2016-02-24 | $3.64B 10-K · filed 2015-02-27 |
| 2014-09-28 | $3.64B 10-Q · filed 2014-11-10 | |
| 2014-06-29 | $3.64B 10-Q · filed 2014-08-12 | |
| 2014-03-30 | $3.64B 10-Q · filed 2014-05-13 | |
| 2013-12-31 | $3.64B 10-K · filed 2015-02-27 | |
| 2013-09-29 | $3.64B 10-Q · filed 2013-11-13 | |
| 2013-06-30 | $3.64B 10-Q · filed 2013-08-14 | |
| 2013-03-31 | $3.64B 10-Q · filed 2013-05-15 | |
| 2012-12-31 | $0.00 10-K · filed 2014-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |